Literature DB >> 9466952

Substrate inhibition of nitric oxide synthase in pulmonary artery endothelial cells in culture.

Y Su1, M Couch, E R Block.   

Abstract

The effects of arginine on nitric oxide synthase (NOS) activity and NO production were studied in pulmonary artery endothelial cells (PAEC). Incubation of PAEC with 0-100 microM arginine increased NO production, detected as nitrite in the culture medium, in a dose-dependent manner. In contrast, incubation with concentrations of arginine in excess of 100 microM resulted in a reversible dose-dependent inhibition of NO production, even though intracellular arginine content increased in these cells. The NOS enzyme kinetics were studied in a total membrane preparation and in purified NOS protein and revealed that the Km of arginine as a substrate for NOS is 3-5 microM, the Vmax occurred at 100 microM arginine, and substrate inhibition occurred at >100 microM arginine. Oxyhemoglobin, carboxy-PTIO, catalase, SOD, citrulline, hydroxyarginine, and D-arginine did not change NOS kinetics. These results indicate that substrate inhibition of eNOS exists in porcine PAEC in vitro.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9466952     DOI: 10.1006/niox.1997.0151

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  3 in total

1.  Essential role of L-arginine uptake and protein tyrosine kinase activity for NO-dependent vasorelaxation induced by stretch, isometric tension and cyclic AMP in rat pulmonary arteries.

Authors:  D Hucks; N M Khan; J P Ward
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Critical dependence of the NO-mediated component of cyclic AMP-induced vasorelaxation on extracellular L-arginine in pulmonary arteries of the rat.

Authors:  D Hucks; J P Ward
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

3.  Extracellular L-arginine is required for optimal NO synthesis by eNOS and iNOS in the rat mesenteric artery wall.

Authors:  Andrew MacKenzie; Roger M Wadsworth
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.